NCT07823556Active, not recruiting
The Role of Transforming Growth Factor- Beta (TGF- β) Expression in Renal Biopsy of Lupus Nephritis Patients
Source: ClinicalTrials.gov · Last updated 16 Sept 2026
Brief summary (registry, in English)
To investigate the possible role of TGF-β expression in renal biopsy and it's relation with fibrosis, activity and chronicity indices
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 14 Feb 2025
- Start date
- 31 May 2026
- Primary completion date
- 30 Jul 2027
- Lead sponsor
- Ain Shams University
- Diseases
- Lupus (SLE)
- NCT number
- NCT07823556
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 31 May 2026 to the primary completion date, 30 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Ongoing or previous chemotherapy treatment for cancer.
Other illness
- Patients with any other Rheumatological diseases such as other autoimmune CT diseases or vasculitides
Other
- Pregnancy.
- Any other causes of CKD or AKI ( acute kidney injury).
Who the study is looking for
- SLE patients who fulfilled EULAR/ACR 2019 Classification Criteria for Systemic Lupus Erythematosus , having lupus nephritis.
- Adult population with age group from 18 to 50 years old.
Age in the registry: 18 years to 50 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ain Shams University Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.